Assenagon Asset Management’s Adaptive Biotechnologies ADPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$512K Buy
+23,883
New +$366K ﹤0.01% 1069
2025
Q4
Sell
-44,488
Closed -$666K 1146
2025
Q3
$666K Buy
+44,488
New +$542K ﹤0.01% 1003
2024
Q2
Sell
-844,852
Closed -$2.71M 1408
2024
Q1
$2.71M Hold
844,852
0.01% 770
2023
Q4
$4.14M Sell
844,852
-19,885
-2% -$90.7K 0.01% 687
2023
Q3
$4.71M Buy
864,737
+818,262
+1,761% +$5.41M 0.01% 597
2023
Q2
$312K Buy
46,475
+19,815
+74% +$147K ﹤0.01% 1226
2023
Q1
$235K Buy
+26,660
New +$235K ﹤0.01% 1345

Other funds holding ADPT

Assenagon Asset Management's ADPT Position: Q2 2026 in Review

Assenagon Asset Management opened a new position in Adaptive Biotechnologies (ADPT) in Q2 2026: 23,883 shares worth $512K. The stake represents ﹤0.01% of the portfolio and ranks #1069 among its holdings. This is a return to the name: Assenagon Asset Management previously reported a position in ADPT as recently as Q3 2025.

Assenagon Asset Management first reported a position in ADPT in Q1 2023 and has held it in 7 quarters since. The position peaked at $4.71M in Q3 2023. 301 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Assenagon Asset Management held 23,883 shares of Adaptive Biotechnologies worth $512K as of Q2 2026.
  • Adaptive Biotechnologies was a new Assenagon Asset Management position in Q2 2026.
  • Adaptive Biotechnologies made up ﹤0.01% of Assenagon Asset Management's portfolio in Q2 2026, its #1069 holding.
  • Assenagon Asset Management first reported a position in Adaptive Biotechnologies in Q1 2023 and has held it in 7 quarters since.
  • Assenagon Asset Management's Adaptive Biotechnologies position peaked at $4.71M in Q3 2023.
  • 301 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Assenagon Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.